The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke

Hirano, Tetsuya; Yamori, Yukio; Kanai, Noriko; Umetsu, Teruhiko; Nishio, Shintaro

doi:10.1007/bf03159984

Cited by 6 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In human medicine, long-term administration of BPS has been approved as a treatment for chronic arterial occlusion [16] and primary pulmonary hypertension [2,8,16]. In addition, oral administration of BPS can be used as a therapeutic treatment for secondary precapillary pulmonary hypertension [17], cerebral infarction [9,13], glomerulonephritis [12,28], diabetic nephropathy [29] and atherosclerotic vascular damage in coronary artery disease [23]. In heart failure with pressure overload, compensated concentric hypertrophy in the left ventricular progresses due to the increase in pressure after overload.…”

mentioning

confidence: 99%

Effect of Long-term Administration of a Prostacyclin Analogue (Beraprost Sodium) on Myocardial Fibrosis in Dahl Rats

Kaneshige

Saida

Tanaka

et al. 2007

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. Beraprost sodium (BPS) is an orally active prostacyclin analogue. The effects of BPS on the heart, including coronary circulation improvement, myocardial and vascular protection and anti-fibrosis effect on myocardium interstitium, have previously been demonstrated. However, the effects of BPS on hemodynamics, cardiac function and myocardial contractility in patients in the hypertrophic phase have not been clarified. Therefore, in the present study, the effects of BPS under long-term administration were investigated using the hypertension model of salt-sensitive Dahl rats. Six-week-old Dahl rats were divided into three groups, an 8% high salt diet group treated with BPS (BPS group), an untreated 8% high salt diet group (HHF group) and an untreated 0.3% low salt diet group (Control group), and observations were conducted until 17 weeks of age. In the BPS and HHF groups, the survival rates after 11 weeks of high salt diet intake were 87.5% and 47.1%, respectively (p<0.05). At 17 weeks of age, the atrial systolic peak velocity/early diastolic peak velocity and heart weight index of the BPS group decreased significantly compared with the HHF group (p<0.05). The HHF group exhibited significantly more severe myocardial fibrosis mainly in the endocardial layer of the left and right ventricles compared with the BPS and Control groups (p<0.05). In the present study, long-term BPS administration preserved diastolic function and prevented myocardial interstitial fibrosis in the non-compensatory phase. The results of the present study suggest that BPS is effective for treatment of hypertensive cardiac hypertrophy. KEY WORDS: beraprost sodium, Dahl rat, echocardiography, hypertension, myocardial fibrosis.J. Vet. Med. Sci. 69(12): 1271-1276, 2007 Prostacyclin is found in all body tissues and body fluids and is the major metabolite of arachidonic acid in the vasculature [6,16]. It is a potent vasodilator that affects both systemic and pulmonary circulations. Prostacyclin also prevents vascular smooth muscle proliferation and inhibits platelet adhesion and aggregation [6]. These features make it a very attractive substance for treatment of various cardiovascular diseases [6,15,16,20]. Beraprost sodium (BPS) is an orally active prostacyclin analogue that was discovered and developed by Toray Industries in Japan [1,16]. In human medicine, long-term administration of BPS has been approved as a treatment for chronic arterial occlusion [16] and primary pulmonary hypertension [2,8,16]. In addition, oral administration of BPS can be used as a therapeutic treatment for secondary precapillary pulmonary hypertension [17], cerebral infarction [9,13], glomerulonephritis [12,28], diabetic nephropathy [29] and atherosclerotic vascular damage in coronary artery disease [23]. In heart failure with pressure overload, compensated concentric hypertrophy in the left ventricular progresses due to the increase in pressure after overload. As a result, then the interstitial fibrosis changes the myocardial structure [21,26,27]. In addition, th...

show abstract

mentioning

confidence: 99%

Effect of Long-term Administration of a Prostacyclin Analogue (Beraprost Sodium) on Myocardial Fibrosis in Dahl Rats

Kaneshige

Saida

Tanaka

et al. 2007

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

show abstract

“…It possesses benzofurane ring in its structure 19,20 . The drug which is in clinical trial in Europe and USA presently, inhibits platelet aggregation induced by ADP, collagen and arachidonic acid 21 .…”

Section: Introductionmentioning

confidence: 99%

Synthesis and biological evaluation of some dibenzofuran-piperazine derivatives

Yurttaş

Mohsen

Özkan

et al. 2015

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

In the present paper, a novel series of dibenzofuran-piperazine derivatives were synthesized via the treatment of N-(2-methoxy-3-dibenzofuranyl)-2-chloroacetamide with substituted piperazine derivatives. The chemical structures of the compounds were elucidated by 1 H NMR, 13C NMR, mass spectral data; elemental analysis and HPLC analysis. Each derivative was evaluated for antiplatelet activity and anticholinesterase activity. Compound 2 m with 2-furoyl moiety exhibited high percentage inhibition as much as standard drug aspirin on arachidonic acid (AA)-induced platelet aggregation. None of the compounds presented significant inhibitor effect on collagen-induced platelet aggregation. Furthermore, the anticholinesterase activity of the compounds was determined and they did not show promising inhibitor activity compared with standard drug donepezil.

show abstract

Beraprost sodium, an analogue of prostacyclin, induces the expression of mitogen-activated protein kinase phosphatase and inhibits the proliferation of cultured mesangial cells

Togawa

Haneda

Araki

et al. 1997

European Journal of Pharmacology

View full text Add to dashboard Cite

The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke

Cited by 6 publications

References 31 publications

Effect of Long-term Administration of a Prostacyclin Analogue (Beraprost Sodium) on Myocardial Fibrosis in Dahl Rats

Effect of Long-term Administration of a Prostacyclin Analogue (Beraprost Sodium) on Myocardial Fibrosis in Dahl Rats

Synthesis and biological evaluation of some dibenzofuran-piperazine derivatives

Beraprost sodium, an analogue of prostacyclin, induces the expression of mitogen-activated protein kinase phosphatase and inhibits the proliferation of cultured mesangial cells

Contact Info

Product

Resources

About